-- Complete a debt or equity financing
-- Submit an application for premarket approval, or PMA, to the FDA for
the treatment of atrial fibrillation
-- Establish an installed base of up to 100 consoles in the United States
CryoCor did not provide revenue guidance for 2008 as a result of the difficulty in projecting the time required to open new centers and project utilization for the new cryoablation technology. CryoCor believes that a large installed base of consoles in the United States will be necessary to generate significant revenues.
Product revenue for the year ended December 31, 2007 decreased $282,000 to $258,000 compared to $540,000 for the same period in 2006 primarily due to the reduced sales activities in Europe as the Company shifted to a distributor arrangement and closed its German subsidiary during 2006.
Collaboration revenue for the year ended December 31, 2007 was $333,000 compared to $0 for the same period in 2006 due to the partial recognition of an advance payment received under the Company's development and license agreement with BSC.
Deferred revenue increased from $78,000 at December 31, 2006 to $206,000 at December 31, 2007 due to the advance payment of $500,000 received against development milestones under the Company's development and license agreement with BSC, of which $167,000 remains deferred at December 31, 2007.
Cost of sales for the year ended December 31, 2007 increased $242,000
to $2.7 million compared to $2.5 million for the same period in 2006. Cost
of sales primarily consists of materials, labor and overhead costs
associated with the manufacturing and warranty of the Company's products.
The increase in costs of sales from 2006 to 2007 was mainly due to higher
headcount needed as a result of the increase in product manufacturing. If
the Company's products are succe
|SOURCE CryoCor, Inc.|
Copyright©2008 PR Newswire.
All rights reserved